Edition:
United Kingdom

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

94.05USD
5:29pm BST
Change (% chg)

$0.63 (+0.67%)
Prev Close
$93.42
Open
$93.40
Day's High
$94.64
Day's Low
$93.40
Volume
403,867
Avg. Vol
1,776,787
52-wk High
$125.84
52-wk Low
$83.25

Select another date:

Fri, Sep 21 2018

BRIEF-Abbvie Receives Positive CHMP Opinion Fo Chemotherapy-Free Combination Of Venclyxto With Rituximab

* ABBVIE RECEIVES POSITIVE CHMP OPINION FOR A NOVEL, CHEMOTHERAPY-FREE COMBINATION OF VENCLYXTO® (VENETOCLAX TABLETS) WITH RITUXIMAB AS A TREATMENT WITH A FIXED DURATION FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY

EU approves fifth copy of AbbVie's $18 billion drug Humira

LONDON Europe has approved a fifth copy of AbbVie's $18-billion (£13.7 billion)-a-year biologic drug Humira – the world's best-selling prescription medicine – ramping up competition among makers of less-expensive biotech drugs.

EU approves fifth copy of AbbVie's $18 billion drug Humira

LONDON Europe has approved a fifth copy of AbbVie's $18-billion-a-year biologic drug Humira – the world's best-selling prescription medicine – ramping up competition among makers of less-expensive biotech drugs.

UPDATE 1-EU approves fifth copy of AbbVie's $18 bln drug Humira

* European Humira sales around $4.4 bln a year (Adds details on biosimilars market in Europe, graphic)

Mylan, Fujifilm win EU okay for copy of AbbVie's Humira

LONDON, Sept 20 Mylan and Fujifilm Kyowa Kirin Biologics said on Thursday they had won European approval to market a cheaper copy of AbbVie's $18-billion-a-year biologic drug Humira, the world's best-selling prescription medicine.

California insurance regulator sues AbbVie alleging Humira kickbacks

Insurance Commissioner Dave Jones on Tuesday filed a complaint on behalf of the State of California against AbbVie Inc, alleging the drugmaker gave illegal kickbacks to healthcare providers to prescribe its blockbuster drug, Humira.

UPDATE 1-California insurance regulator sues AbbVie alleging Humira kickbacks

Sept 18 Insurance Commissioner Dave Jones on Tuesday filed a complaint on behalf of the State of California against AbbVie Inc, alleging the drugmaker gave illegal kickbacks to healthcare providers to prescribe its blockbuster drug, Humira.

California insurance commissioner sues AbbVie over Humira

Sept 18 Insurance Commissioner Dave Jones on Tuesday filed a complaint on behalf of the State of California against AbbVie Inc, alleging the drugmaker gave illegal kickbacks to healthcare providers to prescribe its blockbuster drug, Humira.

AbbVie doubles down on cancer project with biotech group Argenx

BRUSSELS Biotech group Argenx said on Wednesday U.S. pharma group AbbVie had exercised an exclusive option to develop and commercialize one of its experimental drugs which could lead to payments of up to $625 million.

AbbVie doubles down on cancer project with biotech group Argenx

BRUSSELS Biotech group Argenx said on Wednesday U.S. pharma group AbbVie had exercised an exclusive option to develop and commercialise one of its experimental drugs which could lead to payments of up to $625 million(490.08 million pounds).

Select another date: